一品红：子公司创新药APH03621片获临床试验批准

Core Viewpoint - The announcement indicates that the company's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial application of its innovative drug APH03621, which is a new oral, non-peptide small molecule GnRH antagonist intended for the treatment of endometriosis [1] Group 1 - APH03621 is the first oral small molecule GnRH antagonist approved for clinical trials in China, filling a gap in the market as there are currently no approved GnRH oral small molecule antagonists available domestically [1] - The clinical trial approval is expected to commence shortly, indicating progress in the drug development pipeline [1] - The approval of APH03621 for clinical trials is not anticipated to have a significant impact on the company's short-term financial status or operating performance [1]